Stimulation of human EBV- and CMV-specific cytolytic effector function using allogeneic HLA molecules

Area of Science:

• Immunology
• Virology
• Cell Therapy

Background:

• Viral infections pose significant health risks with limited treatment options for T cell responses.
• Allo-HLA cross-reactivity is known, but priming with allogeneic cells to induce viral peptide/self-HLA restricted T cell responses is not well understood.

Purpose of the Study:

• To investigate if allogeneic human leukocyte antigen (HLA) stimulation can induce a viral peptide/self-HLA restricted cytotoxic T cell response.
• To explore the potential of allogeneic cell stimulation as a cell therapy for augmenting antiviral immunity.

Main Methods:

• Used Epstein-Barr virus (EBV)-seropositive peripheral blood mononuclear cells (PBMCs) stimulated with mismatched allogeneic PBMCs.
• Assessed cytotoxicity of stimulated cells against EBV peptide-loaded autologous target cells and EBV-infected lymphoblastoid cell lines (LCLs).
• Extended the method to elicit cytomegalovirus (CMV)-specific responses to confirm broad applicability.

Main Results:

• Allogeneic HLA stimulation successfully induced EBV-specific cytolytic effector function in PBMCs.
• The technique was also effective in eliciting CMV-specific cytotoxic responses, demonstrating its versatility.
• Confirmed that allogeneic stimulation can elicit responses even from private T cell receptor (TCR) repertoires.

Conclusions:

• Allogeneic cell stimulation can elicit a viral peptide/self-HLA restricted cytotoxic T cell response in humans.
• This method shows promise as a cell therapy to enhance antiviral T cell responses in patients with EBV or CMV infections.